Last reviewed 2026-05-22 · How we verify

Clinagel Potassium Salt (CRILANOMER)

Phase 2 active Small molecule ✓ Verified May 2026

Clinagel Potassium Salt (generic name: CRILANOMER) is a crilanomer drug. It is currently in Phase 2 development for Wound dressing.

Clinagel Potassium Salt works by forming a protective barrier on the wound surface to prevent infection and promote healing.

Clinagel Potassium Salt is a small molecule. It is also known by the synonyms CRILANOMER, CRILANOMER, CRILANOMERE, and CRILANOMERO.

Likelihood of approval

17.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Anti-infectives pathway favourability +2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CRILANOMER
Drug class	crilanomer
Modality	Small molecule
Therapeutic area	Infectious Disease
Phase	Phase 2

Mechanism of action

Imagine a clear plastic wrap that you put over a cut to keep it clean and moist. Clinagel Potassium Salt works in a similar way, creating a protective layer on the wound that helps prevent bacteria from getting in and promotes a healthy environment for the wound to heal.

Approved indications

Wound dressing

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Clinagel Potassium Salt CI brief — competitive landscape report
Clinagel Potassium Salt updates RSS · CI watch RSS

Frequently asked questions about Clinagel Potassium Salt

What is Clinagel Potassium Salt?

Clinagel Potassium Salt (CRILANOMER) is a crilanomer drug, indicated for Wound dressing.

How does Clinagel Potassium Salt work?

Clinagel Potassium Salt works by forming a protective barrier on the wound surface to prevent infection and promote healing.

What is Clinagel Potassium Salt used for?

Clinagel Potassium Salt is indicated for Wound dressing.

What is the generic name of Clinagel Potassium Salt?

CRILANOMER is the generic (nonproprietary) name of Clinagel Potassium Salt.

What drug class is Clinagel Potassium Salt in?

Clinagel Potassium Salt belongs to the crilanomer class. See all crilanomer drugs at /class/crilanomer.

What development phase is Clinagel Potassium Salt in?

Clinagel Potassium Salt is in Phase 2.

Drug class: All crilanomer drugs
Therapeutic area: All drugs in Infectious Disease
Indication: Drugs for Wound dressing

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing